Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Best of ASCO® Miami 2016 /
Lung cancer immunotherapy

8th - 10th Jul 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.07.16
Views: 1682
Rating:

Dr Luis Raez - Memorial Cancer Institute, Hollywood, Florida, USA

Dr Raez speaks with ecancertv at the Best of ASCO 2016 about developments in immunotherapy to treat lung cancer.

He describes the improved patient outcomes resulting from combined immunotherapy treatment, and how to cope with associated toxicities.

Dr Raez also highlights the potential of CAR-T cell therapy to treat lung cancer.

Combined courses of ipilimumab and nivolumab have been approved in the UK to treat melanoma, and it was recently reported that PD-L1 selection improved cost effectiveness of nivolumab as a single agent against NSCLC.

 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation